Answers are grounded in this paper and cite their sources.
In this 48-week, single-arm trial, open-label cariprazine (1.5-4.5 mg/day) treatment was generally safe and well tolerated with no new safety concerns associated with long-term treatment.
No takes yet. Share an insight, caveat, or question.
Durgam et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: